AMSTERDAM, May 24, 2018 /CNW/ - New research from Griffith University, Australia, publishedtoday in the Journal of Alternative and Complementary Medicine, shows a multispecies-probiotic formulation to improve the quality of life of hay fever patients.
The researchers investigated whether the probiotic formulation
Nic West, lead author of the research from Griffith University; "What is very promising is that we saw great consistency among study outcomes. Key rhinitis measurements along with symptom severity and medication load, all decreased during the study. The positive study outcomes might be explained by the multistrain nature of the probiotic. We know that in allergies there is a reduction in microbial diversity. By exposing people to a multistrain formulation, with a broad number of probiotic bacteria, we may have a stronger effect on the immune system."
Hay fever is a global health problem affecting between 10% - 30% of the population, with increasing prevalence. Hay fever has a serious impact on daily life and presents a substantial financial burden to patients and the healthcare system. Although not a life-threatening disease on its own, uncontrolled hay fever can increase the risk of life threatening asthma during high pollen events, such as storms. Current treatment options, such as antihistamines, are costly, may not completely resolve symptoms and do not tackle the underlying cause.
West: "There is increasing evidence that show probiotics have a positive effect on the mucosal immune system, particularly in relation to allergies, and this evidence is going to grow. In the future, probiotics are likely to play an integral role in helping people manage their hay fever. Preventative use of probiotics in the long term can help control the severity of symptoms."
SOURCE Winclove Probiotics B.V.
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All